![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:9391M Cambridge Antibody Tech Group PLC 12 November 2001 01/CAT/20 EMBARGOED 07.00 GMT, 02.00 EST Monday 12 November 2001 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263 233 Weber Shandwick Square Mile (Europe) David Glover, Medical Director Tel: +44 (0) 20 7601 1000 John Aston, Finance Director Kevin Smith Rowena Gardner, Head of Corporate Communications Graham Herring Genzyme BMC Communications/The Trout Group (USA) Bo Piela (media) Tel: 001 212 477 9007 Tel: 001 617 252 7785 Brad Miles, ext 17 (media) Sally Curley (investors) Brandon Lewis, ext.15 (investors) Tel: 001 617 591 7140 CAMBRIDGE ANTIBODY TECHNOLOGY AND GENZYME GENERAL INITIATE PHASE I/II CLINICAL TRIAL OF CAT-192 Melbourn, UK and Cambridge, Mass... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) and Genzyme General (NASDAQ: GENZ) today announce that they have initiated a Phase I/II clinical trial to assess the safety and efficacy of the human anti-TGFb monoclonal antibody CAT-192 for the treatment of diffuse systemic sclerosis. Diffuse systemic sclerosis, a form of scleroderma, is a chronic, life-threatening disorder caused by the production of excess collagen which leads to scarring of the skin and internal organs. Eighty percent of those affected by this disease are women between the ages of 25-55. About 40 percent of all patients with this disorder die within ten years of diagnosis. There is currently no effective therapy for the disease, which affects an estimated 300,000 people worldwide. The partners have begun a randomised, double-blind, placebo-controlled trial that evaluates three different dose levels of CAT-192. Each patient will receive four infusions administered six weeks apart over the trial period. In addition to evaluating safety, the trial will study the effect of CAT-192 on several clinical and biologic markers of disease progression. A total of 36 patients will be enrolled in the trial, which will take place at a total of seven sites in Europe, with the possible addition of other sites. Cambridge Antibody Technology and Genzyme General have been working in partnership to develop and commercialise human TGFb monoclonal antibodies for the treatment of diffuse systemic sclerosis since September 2000. -ENDS- Notes to Editors: Cambridge Antibody Technology (CAT) CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 250 people. CAT is listed on the London Stock Exchange and on NASDAQ since June 2001. CAT raised #41m in its IPO in March 1997 and #93m in a secondary offering in March 2000. CAT has an advanced platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs and to utilise antibodies as tools for target validation. Six human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT has alliances with a large number of biotechnology and pharmaceutical companies to discover develop and commercialise human monoclonal antibody-based products. CAT has also licensed its proprietary human phage antibody libraries to several companies for target validation and drug discovery. CAT's partners include: Eli Lilly, Pfizer, Abbott, Genetics Institute, Wyeth-Ayerst, Human Genome Sciences, Pharmacia, Oxford GlycoSciences, Genzyme, Immunex, Zyomyx, Elan, Xerion and Merck & Co. Genzyme General Genzyme General develops and markets therapeutic products and diagnostic products and services. Genzyme General has five therapeutic products on the market and a strong pipeline of products in development focused on the treatment of genetic disorders and other chronic debilitating diseases with well-defined patient populations. Genzyme General is a division of the biotechnology company Genzyme Corporation. Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved. This press release contains statements about Cambridge Antibody Technology Group plc (CAT) that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements These forward looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions